| Business Summary | | Genetic
Vectors,
Inc.
(GVEC)
is
a
biotechnology
company
that
specializes
in
the
discovery
of
genetic
patterns
from
which
it
intends
to
develop
systems
to
determine
disease
risk,
drug
resistance,
and
therapeutic
response.
The
Company
developed
and
currently
is
marketing
the
EpiDNA
product
line
as
a
quality
control
tool
for
the
biopharmaceutical
industry.
Pharmacogenomics
(genomic
discovery
for
healthcare
applications)
utilizes
genetic
information
to
identify
the
subtle
changes
in
genetic
structure
that
influence
disease
susceptibility,
drug
resistance,
and
therapeutic
response.
The
technology
is
useful
for
genetic
screening
of
individuals
and
pathogenic
organisms
and
monitoring
the
purity
of
biopharmaceuticals.
The
Company's
EasyID
genetic
screening
products
are
designed
to
study
disease
risk
assessment,
drug
resistance,
and
drug
responsiveness.
Initial
areas
of
development
include
the
genetic
basis
of
cardiovascular
disease,
pathogenic
yeast
infections,
and
autoimmune
diseases. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genetic
Vectors,
Inc.
is
a
development
stage
biotechnology
company
that
intends
to
specialize
in
the
development
of
technologies
and
products
addressing
the
pharmacogenomics,
clinical
diagnostic,
research
and
industrial
markets.
For
the
nine
months
ended
9/30/00,
total
revenue
rose
32%
to
$96
thousand.
Net
loss
totaled
$5.3
million,
up
from
$1.7
million.
Results
reflect
higher
sales,
offset
by
increased
amortization
and
stock
issuance
costs. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| Mead McCabe, Sr., Ph.D., 63 Chairman | $152K | Mead McCabe, Jr., 34 CEO,
Chief Financial Officer, Sec., Director | 132K | Eric Wilkinson, 41 Pres,
Director | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|